Download PDF
Thromb Haemost 1991; 65(04): 382-388
DOI: 10.1055/s-0038-1648157
Original Article
Schattauer GmbH Stuttgart

Western Blot Analyses of Prekallikrein and its Activation Products in Human Plasma

Dulce Veloso
The Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA, and the Department of Medicine, The Graduate Hospital, Philadelphia, PA, USA
,
Robert W Colman
The Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA, and the Department of Medicine, The Graduate Hospital, Philadelphia, PA, USA
› Author Affiliations
Further Information

Publication History

Received: 22 May 1990

Accepted after revision 11 December 1990

Publication Date:
02 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Prekallikrein (PK), a zymogen of the contact system, and its activation products, kallikrein (KAL), KAl-inhibitor complexes and fragments containing KAL epitope(s) have been detected in human plasma by immunoblotting with a monoclonal anti-human plasma PK antibody, MAb 13G1L. Detection of antigen-MAb 13G11 complexes with peroxidase-conjugated anti-IgG showed that the two variants of PK (85- and 88-kDa) are the only major antigen species in normal, non-activated plasma. Upon plasma activation with kaolin, the intensity of the PK bands decreased with formation of complexes of KAL with CL inhibitor (C1 INH) and α2-rrtzcroglobulin (α2M) identical to those formed by the purified proteins. Immunoblots of normal plasma showed good correlation between the PK detected and the amount of plasma assayed. Increasing amounts of KAL incubated with a constant volume of PK-deficient plasma showed increasing amounts of KAL and of KAL-C1 INH and KAL-α2M complexes. Complexes of KALantithrombin III (ATIII) and the ratio of KALα2M/ KAL-CL INH were higher in activated CL INH-deficient plasmas than in activated normal plasmas. Protein resolution by 3-12% gradient SDS-PAGE and epitope detection with [125I]MAb 13G11 showed four KALα2M species and a 45-kDa fragment(s) in both surface-activated normal plasma and complexes formed by purified KAL and α2M. Immunoblots of activated plasma also showed bands at the position of KALCL INH and KALATIII complexes. When α1-antitrypsin Pittsburgh (cα1-AT, Pitts) was added to plasma before activation, KAL-α1-ALPitts was the main complex. The non-activated normal plasma revealed only an overloaded PK band. This is the first report of an antibody that recognizes KAL epitope(s) in KAL-α2M, KALATIII and KALa1-α1Pitts complexes and in the 45-kDa fragment(s). Therefore, MAb 13G11 should be useful for studying the structure of these complexes as well as the mechanism of complex formation. In addition, immunoblotting with MAb 13G11 would allow detection of KAl-inhibitor complexes in patient plasmas as indicators of activation of the contact system.

 

  • References

  • 1 Colman RW. Surface-mediated defense reactions, The plasma contact activation system. J Clin Invest 1984; 73: 1249-1253
    CrossrefPubMedGoogle Scholar
  • 2 Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood 1987; 70: 11-15
    PubMedGoogle Scholar
  • 3 Schapira M, Scott CR, Colman RW. Contribution of plasma protease inhibitors to the inactivation of kallikre, in plasma. J Clin Invest 1982; 69: 462-468
    CrossrefPubMedGoogle Scholar
  • 4 van der GraafF, Koedam JA, Bouma BN. Inactivation of kallikrein in human plasma. J Clin Invest 1983; 71: 149-158
    CrossrefPubMedGoogle Scholar
  • 5 Meijers JCM, Kanters DHAJ, Vlooswijk RAA, van Erp HE, Hessing M, Bouma BN. Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Biochemistry 1988; 27: 4231-4237
    CrossrefPubMedGoogle Scholar
  • 6 Ohlsson K, Laurell CB. The disappearance of enzyme-inhibitor complexes from the circulation of man. Clin Sci Mol Med 1976; 51: 87-92
    PubMedGoogle Scholar
  • 7 Lollar R, Whyte GO. Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium. Possible role in the inactivation of thrombin by antithrombin III. J Clin Invest 1980 66. 1222-1230
    PubMedGoogle Scholar
  • 8 Fuchs HE, Michalopoulos GK, Pizzo SV. Hepatocyte uptake of α1 proteinase inhibitor-trypsin complexes in vitro: evidence for a shared uptake mechanism for proteinase complexes of α1-proteinase inhibitor and antithrombin III. J Cell Biochem 1984; 25: 231-243
    CrossrefPubMedGoogle Scholar
  • 9 Roche PA, Pizzo SV. Characteruation of α2-macroglobulin-plasmin complexes: complete subunit cleavage alters receptor recognition in vivo and in vitro. Biochemistry 1987; 26: 486-491
    CrossrefPubMedGoogle Scholar
  • 10 Lewin MR, Kaplan AP, Harpel PC. Studies of CL inactivator-plasma kallikrein complexes in purified system and in plasma. Quantification by an enzyme-linked differential antibody immunosorbent assay. J Biol Chem 1983 258. 6415-6421
    PubMedGoogle Scholar
  • 11 Harpel PC, Lewin MR, Kaplan AP. Distribution of plasma kallikrein between C1 inactivator and α2-macroglobulin in plasma utilizing a new assay for ;2-macdctoglobulin complexes. J Biol Chem 1985; 260: 4257-4263
    PubMedGoogle Scholar
  • 12 Colman RW, Edelmatr R, Scott CR, Gilman RH. Plasma kallikrein activation and inhibition during typhoid fever. J Clin Invest 1978; 6l: 287-296
    PubMedGoogle Scholar
  • 13 Rao AK, Schapiro M, Clements ML, Newiarowski S, Budzynski AZ, Schmaier AH, Harpel PC, Blackwelder WC, Scherrer J-R, Sobel E, Colman RW. A prospective study of platelets and plasma proteolytic systems during the early stages of Rocky Mountain spotted fever. N Engl J Med 1988; 318: 1021-1029
    CrossrefPubMedGoogle Scholar
  • 14 Nijens JH, Huijbregts CCM, Cohen M, Navis GO, de Vries A, Eerenberg AJM, Bakker JC, Hack CE. Detection of activation of the contact system of coagulation in vitro and in vivo: quantitation of activated Hageman factor-Cl-inhibitor and kallikrein-C1-inhibitor complexes by specific radioimmunoassays. Thromb Haemostas 1987; 58: 778-785
    PubMedGoogle Scholar
  • 15 Alving BM, Hojima Y, Pisano JJ, Mason BL, Buckingham Jr RE, Mozen MM, Finlayson JS. Hypotension associated with prekallikrein activator (Hageman factor fragments) in plasma protein fraction. N Engl J Med 1978; 299: 66-70
    CrossrefPubMedGoogle Scholar
  • 16 Gallimore MJ, Aasen AO, Lyngaas KHN, Larsbraaten M, Amundsen E. Falls in plasma levels of prekallikrein, high molecular weight kininogen, and kallikrein inhibitors during lethal endotoxin shock in dogs. Thromb Res 1978; 12: 307-318
    CrossrefPubMedGoogle Scholar
  • 17 Ltimmle B, Tian TTI, Ritz R, Duckert E. Plasma prekallikrein, factor XII, antithrombin III, Cl-inhibitor and α2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC). Am J Clin Pathol 1984; 82: 396-404
    CrossrefPubMedGoogle Scholar
  • 18 Veloso D, Tseng SX, Craig AR, Colman RW. Binding of a monoclonal anti-human plasma prekallikrein antibody to the complexes of kallikrein with CL inhibitor and α2macroglobulin analyzed by immunoblot and “sandwich” assays. Adv Exp Med Biol 1989; 247 Pt A 499-505
    PubMedGoogle Scholar
  • 19 Owen MC, Brennan SO, Lewis JH, Carrel RW. Mutation of antitrypsin to antithrombin. N Engl J Med 1983; 309: 694-698
    CrossrefPubMedGoogle Scholar
  • 20 Liimmle B, Berretini M, Griffin JH. Enhanced specificity of immunoblotting using radiolabeled antigen overlay: studies of blood coagulation factor XII and prekallikrein in plasma. Anal Biochem 1986; 156: 118-125
    CrossrefPubMedGoogle Scholar
  • 21 Veloso D, Silver LD, Hahn S, Colman RW. A monoclonal antihuman plasma prekallikrein antibody that inhibits activation of prekallikrein by factor XIIa on a surface. Blood 1987; 70: 1053-1062
    PubMedGoogle Scholar
  • 22 Rosenberg S, Barr PJ, Najarian RC, Hallewell RA. Synthesis in yeast of functional oxidation-resistant mutant of human α1-antitrypsin. Nature (London) 1984; 312: 77-80
    CrossrefPubMedGoogle Scholar
  • 23 Hojima Y, Thnkersley DL, Miller-Anderson M, Pierce JY, Pisano JJ. Enzymatic properties of human Hageman factor fragment with plasma prekallikrein and synthetic substrates. Thromb Res 1980; 18: 417-430
    CrossrefPubMedGoogle Scholar
  • 24 Harpel PC. Cl-inhibitor. Methods Enzymol 1976; 45: 751-760
    PubMedGoogle Scholar
  • 25 Fraker PM, Speck Jr JC. Protein and cell membrane iodinations with a sparingly soluble chloroamide, L, 3, 4, 6-tetrachloro, 3α, 6αdiphenylglycoluril. Biochem Biophys Res Commun 1978; 80: 849-857
    CrossrefPubMedGoogle Scholar
  • 26 Knight LC, Budzynski AZ, Olexa SA. Radiolabelling of fibrinogen using the iodogen technique. Thromb Haemostas 1981; 46: 593-596
    PubMedGoogle Scholar
  • 27 Hall PK, Roberts RC. Physical and chemical properties of human plasma α2-rtzctoglobulin. Biochem J 1978; 173: 27-38
    CrossrefPubMedGoogle Scholar
  • 28 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 29 Towbin H, Staehelin I, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4354
    CrossrefPubMedGoogle Scholar
  • 30 Burnette WN. “Western Blotting”. Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 1981; 112: 195-203
    PubMedGoogle Scholar
  • 31 Johnson DA, Gautsch JW, Sportsman JR, Elder JH. Improved technique utilizing nonfat dry milk for analysis of proteins and nucleic acids transferred to nitrocellulose. Gene Anal Tech 1984; 1: 3-8
    CrossrefPubMedGoogle Scholar
  • 32 Berretini M, Liimmle B, White I, Heeb MJ, Schwarz HP, Zuran B, Curd J, Griffin JH. Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood 1986; 68: 455-462
    PubMedGoogle Scholar
  • 33 Mandle Jr RI, Kaplan AP. Human plasma prekallikrein. Mechanism of activation by Hageman factor and participation in Hageman factordependent fibrinolysis. J Biol Chem 1977 252. 6097-6104
    PubMedGoogle Scholar
  • 34 Hojima Y, Pierce JY, Pisano JJ. Purification and characteraation of multiple forms of human plasma prekallikrein. J Biol Chem 1985; 260: 400-406
    PubMedGoogle Scholar
  • 35 Harpel PC. Blood proteolytic eruyme inhibitors: their role in modulating blood coagulation and fibrinolytic enzyme pathways. In: Hemostasis and Thrombosis Colman RW, Hirsch J, Marder V, Salzman E. eds J. B. Lippincott Company; Philadelphia, PA: 1987: 219
  • 36 Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema. Absence of serum inhibitor of Cl-esterase. Am J Med 1963; 35: 37-44
    PubMedGoogle Scholar
  • 37 Travis J, Salversen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983; 52: 655-709
    CrossrefPubMedGoogle Scholar
  • 38 Curd JG, Prograis Jr LJ, Cochrane CG. Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J Exp Med 1980; 152: 742-747
    CrossrefPubMedGoogle Scholar
  • 39 Landerman NS, Webster ME, Becker EL, Ratcliffe HE. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy 1962 33. 330-341
    PubMedGoogle Scholar
  • 40 Schapira M, Silver LD, Scott CF, Schmaier AH, Prograis Jr LJ, Curd JG, Colman RW. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 1983; 308: 1050-1053
    CrossrefPubMedGoogle Scholar
  • 41 Banett AJ, Starkey PM. The interaction of α2-rnocroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J 1973 133. 709-724
    PubMedGoogle Scholar
  • 42 Scott CF, Carrel RW, Glaser CB, Kueppers F, Lewis JH, Colman RW. Alpha-L-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein and factor XIII. J Clin Invest 1986; 77: 631-634
    PubMedGoogle Scholar